Place in therapy for liraglutide and saxagliptin for type 2 diabetes.

Background: The release of incretin based therapeutic entities has brought the possibility to offer control of the disease by augmenting a natural process in the body that has become deficient with type 2 diabetes. Liraglutide, an incretin mimetic, and saxagliptin, a dipeptidyl peptidase-4 inhibitor, have been approved and introduced to the market.

Objectives: To (a) review the efficacy and safety data of for the treatment of type 2 diabetes, and (b) recommend their place in therapy.